• Product NameRecombinant human B7H7
• Host SpeciesHEK293
• Purification> 95% by Tris-Bis PAGE;> 95% by SEC-HPLC
• Biological ActivityMeasured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50?for this effect is 0.075-0.75 ��g/mL.
• Endotoxin< 1 EU/μg of the protein by LAL method.
• Immunogen DescriptionIle23-Asn344
• Target NameB7H7
• Alternative Names    B7H7; B7-H7; HERV-H LTR-associating 2; HERV-H LTR-associating protein 2; HHLA2; Human endogenous retrovirus-H long terminal repeat-associating protein 2
• Accession No. Uniprot:Q9UM44
  Gene ID:11148
• UniprotQ9UM44
• Gene ID11148
• Target Species human
• Calculated MW 37 KDa
• Tag Info C-His-Tag
• Formulation 0.22 μm filtered solution of PBS, pH 7.4.
• Reconstitution 0.2 mg/mL in sterile PBS, pH7.4
• Storage Aliquot and store at -80˚C. Avoid repeated freeze/thaw cycles.

B7-H7, also known as HHLA2 (HERV-H LTR-associating 2), is a member of the B7 family of immune regulatory proteins (1, 2). Mature human B7-H7 consists of a 322 amino acid (aa) extracellular domain (ECD) with three immunoglobulin-like domains, a 21 aa transmembrane segment, and a 49 aa cytoplasmic domain (3-5). B7?H7 is constitutively expressed on monocytes and is up-regulated by LPS and IFN-gamma stimulation. It is expressed on LPS/IFN-gamma treated B cells but not on resting B cells (5). B7-H7 binds to cell surface determinants on resting and mature T cells, B cells, and monocytes as well as on immature and mature dendritic cells (5). Soluble B7-H7 inhibits the proliferation of activated CD4+ and CD8+ T cells and their production of IFN-gamma, TNF-alpha, IL-5, IL-10, IL-13, IL-17A, and IL-22 (5).

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting